Stephanie Fradette

Company: Biogen

Job title: Senior Medical Director, Clinical Development

Seminars:

Panel Discussion: Refining Sensitive Primary Outcome Measures & Navigating Innovative Trial Design in ALS 2:00 pm

Pursuing sensitive markers of disease activity and delineating accurate primary outcome measures beyond ALSFRS-R Driving early diagnosis, patient diversity, and decentralized trial design to establish effective patient recruitment Can we capture statistically meaningful changes in an acute timeframe? Balancing length of trial to demonstrate safety and clinical benefitRead more

day: Day One

Interrogating Neurofilament as a Marker of Disease Activity & Treatment Response 8:30 am

Assessing data from tofersen studies to explore the potential utility of neurofilament to enrich or stratify study populations Evaluating the relationship between treatment-induced reductions in neurofilament and clinical outcome measures Exploring neurofilament as an early marker of disease activity in presymptomatic mutation carriersRead more

day: Day One